Natixis Advisors
AMRI

Natixis Advisors’s Albany Molecular Research Inc AMRI Stock Holding History

Natixis Advisors’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-192,601
Closed -$3.61M – 1066
2016
Q4 		$3.61M Buy
192,601
+5,608
+3% +$95.3K 0.04% 504
2016
Q3 		$3.09M Buy
186,993
+15,696
+9% +$233K 0.04% 543
2016
Q2 		$2.3M Buy
171,297
+5,831
+4% +$85.1K 0.03% 588
2016
Q1 		$2.53M Buy
165,466
+3,948
+2% +$61.9K 0.04% 551
2015
Q4 		$3.21M Sell
161,518
-11,862
-7% -$225K 0.05% 462
2015
Q3 		$3.02M Sell
173,380
-1,795
-1% -$36.5K 0.05% 491
2015
Q2 		$3.54M Sell
175,175
-573
-0.3% -$11.1K 0.06% 453
2015
Q1 		$3.09M Buy
175,748
+45,108
+35% +$769K 0.05% 510
2014
Q4 		$2.13M Buy
+130,640
New +$2.4M 0.04% 584

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Natixis Advisors's AMRI Position: Q1 2017 in Review

Natixis Advisors sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 192,601 shares — an estimated $3.61M sold.

Natixis Advisors first reported a position in AMRI in Q4 2014 and held it in 9 quarters. The position peaked at $3.61M in Q4 2016. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

  • Natixis Advisors reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
  • Natixis Advisors sold 192,601 Albany Molecular Research Inc shares in Q1 2017, an estimated $3.61M.
  • Natixis Advisors first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 9 quarters.
  • Natixis Advisors's Albany Molecular Research Inc position peaked at $3.61M in Q4 2016.
  • 139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on Natixis Advisors's 13F filing for Q1 2017, filed 12 May 2017.